Isavuconazonium sulfateIsavuconazonium sulfate
MedChemExpress (MCE)
HY-100373
946075-13-4
BAL8557-002
98.53%
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Room temperature in continental US
may vary elsewhere.
Isavuconazonium sulfate (BAL8557-002) is an orally active broad-spectrum antifungal molecule. Isavuconazonium sulfate is a precursor of the triazole antifungal active molecule Isavuconazole. Isavuconazonium sulfate can be used in the study of invasive aspergillosis, mucormycosis, blastomycosis, and Acanthamoeba keratitis.
Isavuconazonium sulfate (0.006 nM-50 μM) inhibits trophoblast activity of three T4-genotype strains of Acanthamoeba (Ma, CDC:V240 and MEEI 0184) with EC50 vaules of 0.001 μM, 0.037 μM and 0.024 μM, respectively. And (100-200 μM
48 h) has vesicle-extinguishing activity in three tested strains Ma, CDC:V240, and MEEI 0184 with mean minimum vesicle extinguishing concentration (MCC) of 167.1 μM, 136.0 μM, and 187.5 μM, respectively[2]. Isavuconazonium sulfate inhibits bacteria with minimum inhibitory concentration (MIC) [5].
Isavuconazonium sulfate (215 mg/kg
p.o.
Three times a day for 4 days) has anti-R.delemar virus activity in ICR mice infected with mucormycosis[4].
| | | |
| | | | | |
[1]. Kovanda L L, et al. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis[J]. Expert review of clinical pharmacology, 2016, 9(7): 887-897.
[2]. Shing B, et al. Evaluation of Amebicidal and Cysticidal Activities of Antifungal Drug Isavuconazonium Sulfate against Acanthamoeba T4 Strains. Pharmaceuticals (Basel). 2021 Dec 11
14(12):1294. [Content Brief]
[3]. Slain D, et al. Isavuconazonium sulfate: a novel antifungal agent[J]. Current Fungal Infection Reports, 2015, 9: 302-313.
[4]. Luo G, et al. Isavuconazole therapy protects immunosuppressed mice from mucormycosis[J]. Antimicrobial agents and chemotherapy, 2014, 58(4): 2450-2453.
[5]. Scolarici MJ, et al. The Role of Isavuconazonium Sulphate for the Treatment of Blastomycosis: A Case Series and Antifungal Susceptibility. Open Forum Infect Dis. 2022 Apr 27
9(7):ofac220. [Content Brief]